ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky

ARS Pharmaceuticals stock lost more than 23% of its value in a single after-hours session after Neffy® failed to secure any new formulary additions in the July 2026 payer cycle -- a result that contradicted repeated executive coverage projections. NEW YORK, July 6, 2026 /PRNewswire/ --...